These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 7541455)

  • 1. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein.
    Wu JT; Astill ME; Gagon SD; Bryson L
    J Clin Lab Anal; 1995; 9(3):151-65. PubMed ID: 7541455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSA immunoreactivity detected in LNCaP cell medium, breast tumor cytosol, and female serum.
    Wu JT; Zhang P; Astill ME; Wilson LW; Lyons BW; Wu LL; Stephenson R
    J Clin Lab Anal; 1995; 9(4):243-51. PubMed ID: 7562242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
    J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of c-erbB-2 proteins in serum, breast tumor tissue, and SK-BR-3 cell line.
    Wu JT; Zhang P; Astill ME; Lyons BW; Wu LH
    J Clin Lab Anal; 1995; 9(3):141-50. PubMed ID: 7602422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
    Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
    Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients.
    Molina R; Jo J; Filella X; Zanón G; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
    Anticancer Res; 1999; 19(4A):2551-5. PubMed ID: 10470193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers.
    Wu JT; Astill ME; Zhang P
    J Clin Lab Anal; 1993; 7(1):31-40. PubMed ID: 8093903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA 15-3 serum levels in patients with ductal breast carcinoma: relationship with clinicopathological parameters and tumor markers.
    González-Sistal A; Arias JI; Ruibal A
    Int J Biol Markers; 2012; 27(1):47-52. PubMed ID: 21928245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.
    Wu JT; Erickson AJ; Tsao KC; Wu TL; Sun CF
    Ann Clin Lab Sci; 2000 Apr; 30(2):175-8. PubMed ID: 10807161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse.
    Sugano K; Ushiama M; Fukutomi T; Tsuda H; Kitoh T; Ohkura H
    Int J Cancer; 2000 Jul; 89(4):329-36. PubMed ID: 10956406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma.
    Colomer R; Aparicio J; Montero S; Guzmán C; Larrodera L; Cortés-Funes H
    Br J Cancer; 1997; 76(9):1215-20. PubMed ID: 9365172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preoperative serum CA15.3 and CEA levels and clinical-biological parameters in breast tumors].
    Ruibal A; Garrido Pumar M; Arias JI
    Rev Esp Med Nucl; 2006; 25(3):180-3. PubMed ID: 16762272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
    Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
    Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of erbB-2 oncoprotein in human breast cancers by ELISA.
    Nugent A; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
    Biochem Soc Trans; 1992 Feb; 20(1):82S. PubMed ID: 1353039
    [No Abstract]   [Full Text] [Related]  

  • 16. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
    Leitzel K; Teramoto Y; Konrad K; Chinchilli VM; Volas G; Grossberg H; Harvey H; Demers L; Lipton A
    J Clin Oncol; 1995 May; 13(5):1129-35. PubMed ID: 7738618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients.
    Fehm T; Gebauer G; Jäger W
    Breast Cancer Res Treat; 2002 Sep; 75(2):97-106. PubMed ID: 12243512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades.
    Marsigliante S; Muscella A; Ciardo V; Barker S; Leo G; Baker V; Mottaghi A; Vinson GP; Storelli C
    Cancer Lett; 1993 Dec; 75(3):195-206. PubMed ID: 7906196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma.
    Streckfus C; Bigler L; Tucci M; Thigpen JT
    Cancer Invest; 2000; 18(2):101-9. PubMed ID: 10705871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
    Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
    Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.